表紙
市場調查報告書

格林-巴利症候群治療的全球市場:2019年∼2023年

Global Guillain-Barre Syndrome Treatment Market 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 750729
出版日期 內容資訊 英文 111 Pages
訂單完成後即時交付
價格
格林-巴利症候群治療的全球市場:2019年∼2023年 Global Guillain-Barre Syndrome Treatment Market 2019-2023
出版日期: 2018年11月08日內容資訊: 英文 111 Pages
簡介

策略性聯盟的趨勢有助於市場蓬勃發展。製藥公司共同開發用於治療格林 - 巴利症候群的藥物。這些聯盟將加強用於治療格林 - 巴利症候群的新藥的研發活動。Technavio的分析師預測,到2023年格林 - 巴利綜合症治療市場的年複合成長率將超過5%。

本報告提供全球格林-巴利症候群治療市場相關調查分析,市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

第3章 市場情形

  • 市場生態系統
  • 市場特性
  • 市場區隔分析
  • PART04:市場規模
  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情形

第6章 市場區隔:各產品

  • 市場區隔:各產品(2018年∼2023年)
  • 比較:各產品
  • 免疫球蛋白
  • 其他的治療方法
  • 市場機會:各產品

第7章 客戶形勢

第8章 各地區景觀

  • 各地區市場區隔(2018年∼2023年)
  • 各地區比較
  • 南北美洲
  • 歐洲、中東、非洲地區
  • 亞太地區
  • 主要國家
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

第12章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭模式

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • CSL
  • Grifols
  • Kedrion
  • Octapharma
  • Shire

第14章 附錄

  • 調查方法
  • 簡稱的清單

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR30224

About this market

The trend of strategic alliances to help market grow at a flourishing rate. Pharmaceutical companies are working together for the development of medications for the treatment of Guillain-Barre syndrome. These alliances will enhance the R&D activities of new drugs for the management of Guillain-Barre syndrome. Technavio's analysts have predicted that the Guillain-Barre syndrome treatment market will register a CAGR of more than 5% by 2023.

Market Overview

Recent approvals of immunoglobulins

Immunoglobulins are the first line treatment of Guillain-Barre syndrome. The recent approvals of novel immunoglobulins from regulatory bodies are expected to propel the growth of the global Guillain-Barre syndrome treatment market during the forecast period.

Availability of alternate therapies

Currently there is no cure for Guillain-Barre syndrome. The goal of the available treatments is to provide relief from the symptoms of disease. Although the intravenous immunoglobin therapy is more convenient and widely available, it has certain side effects. Hence, some physicians are strongly inclined toward other available plasma exchange procedures for the treatment of Guillain-Barre syndrome.

For the detailed list of factors that will drive and challenge the growth of the Guillain-Barre syndrome treatment market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including CSL and Grifols the competitive environment is quite intense. Factors such as the recent approvals of immunoglobulins and strategic alliances, will provide considerable growth opportunities to Guillain-Barre syndrome treatment manufactures. CSL, Grifols, Octapharma, Shire, and Kedrion are some of the major companies covered in this report.

'With the presence of a considerable number of companies, this market appears to be fragmented. The market will witness the emergence of many international and regional GBS treatment companies who offer therapeutics such as immunoglobulins and other therapeutics. Pharmaceutical companies are working together for the development of medications for the treatment of Guillain-Barre syndrome, which is expected to enhance the R&D activities of new drugs for the management of GB syndrome.'

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
  • PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Immunoglobulins - Market size and forecast 2018-2023
  • Other therapeutics - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: TRENDS

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • CSL
  • Grifols
  • Kedrion
  • Octapharma
  • Shire

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global neurological disorder drugs market
  • Exhibit 02: Segments of global neurological disorder drugs market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Product - Market share 2018-2023 (%)
  • Exhibit 18: Comparison by product
  • Exhibit 19: Immunoglobulins - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 20: Immunoglobulins - Year-over-year growth 2019-2023 (%)
  • Exhibit 21: Other therapeutics - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Other therapeutics - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Market opportunity by product
  • Exhibit 24: Customer landscape
  • Exhibit 25: Market share by geography 2018-2023 (%)
  • Exhibit 26: Geographic comparison
  • Exhibit 27: Americas - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 28: Americas - Year-over-year growth 2019-2023 (%)
  • Exhibit 29: Top 3 countries in Americas
  • Exhibit 30: EMEA - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: EMEA - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Top 3 countries in EMEA
  • Exhibit 33: APAC - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: APAC - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: Top 3 countries in APAC
  • Exhibit 36: Key leading countries
  • Exhibit 37: Market opportunity
  • Exhibit 38: Impact of drivers and challenges
  • Exhibit 39: Vendor landscape
  • Exhibit 40: Landscape disruption
  • Exhibit 41: Vendors covered
  • Exhibit 42: Vendor classification
  • Exhibit 43: Market positioning of vendors
  • Exhibit 44: CSL - Vendor overview
  • Exhibit 45: CSL - Business segments
  • Exhibit 46: CSL - Organizational developments
  • Exhibit 47: CSL - Geographic focus
  • Exhibit 48: CSL - Segment focus
  • Exhibit 49: CSL - Key offerings
  • Exhibit 50: CSL - Key customers
  • Exhibit 51: Grifols - Vendor overview
  • Exhibit 52: Grifols - Business segments
  • Exhibit 53: Grifols - Organizational developments
  • Exhibit 54: Grifols - Geographic focus
  • Exhibit 55: Grifols - Segment focus
  • Exhibit 56: Grifols - Key offerings
  • Exhibit 57: Grifols - Key customers
  • Exhibit 58: Kedrion - Vendor overview
  • Exhibit 59: Kedrion - Business segments
  • Exhibit 60: Kedrion - Organizational developments
  • Exhibit 61: Kedrion - Geographic focus
  • Exhibit 62: Kedrion - Segment focus
  • Exhibit 63: Kedrion - Key offerings
  • Exhibit 64: Kedrion - Key customers
  • Exhibit 65: Octapharma - Vendor overview
  • Exhibit 66: Octapharma - Organizational developments
  • Exhibit 67: Octapharma - Key offerings
  • Exhibit 68: Octapharma - Key customers
  • Exhibit 69: Shire - Vendor overview
  • Exhibit 70: Shire - Business segments
  • Exhibit 71: Shire - Organizational developments
  • Exhibit 72: Shire - Geographic focus
  • Exhibit 73: Shire - Key offerings
  • Exhibit 74: Shire - Key customers